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Background: Bleeding during functional endoscopic sinus surgery is a challenge for the quality of the surgical field
for surgeons. This study aimed to evaluate the effect of desmopressin premedication on blood loss and the quality
of the surgical field in endoscopic sinus surgery.
Methods: A total of 90 American Society of Anesthesiologists physical status I–II patients underwent endoscopic
sinus surgery for chronic sinusitis. They were randomly allocated to receive either desmopressin 0.3 μg/kg or saline
before the operation. Management of anesthesia was achieved with propofol and remifentanil infusions, with
moderate, controlled hypotension. Blood loss and quality of the surgical field were assessed after surgery. Effects of
desmopressin on anesthetic requirements and hemodynamic variables were analyzed.
Results: Blood loss was significantly less in the desmopressin group (mean ± SD, 42 ± 8.7 ml) than in the control
group (70 ± 9.2 ml, P < 0.001). Surgeons were more satisfied with the surgical field in the desmopressin group than
in the control group (median score, 4 [3–5] vs. 7 [6–9], P < 0.001). Requirements for remifentanil and esmolol were
lower in the desmopressin group than in the control group.
Conclusions: Premedication with desmopressin 0.3 μg/kg can effectively reduce bleeding during endoscopic sinus
surgery.
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Functional endoscopic sinus surgery (FESS) is a com-
mon technique for surgical management of chronic rhi-
nosinusitis [1]. Although major blood loss during FESS
is rare, even a small amount of blood may disturb the
surgical view. This disturbance prolongs the operation
time, increases the likelihood of complications, and pos-
sibly results in incomplete surgery [2]. Several tech-
niques have been suggested to improve the surgical field
in endoscopic sinus surgery, such as bipolar diathermy,
topical vasoconstrictors, local injection of epinephrine,* Correspondence: 11139398@qq.com
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unless otherwise stated.and induced hypotension [3,4]. However, none of these
techniques have consistently provided an ideal surgical
field for the surgeon. Bleeding in FESS remains a chal-
lenge for surgeons and anesthesiologists.
Desmopressin (1-deamino-8-D-arginine vasopressin)
has been used as a treatment for mild to moderate
hemophilia and von Willebrand’s disease. Desmopressin
has also been used to reduce the prolonged bleeding
time that often accompanies uremia, hepatic cirrhosis,
and other causes of platelet dysfunction. Hemostatic
effects of desmopressin include increasing plasma con-
centrations of coagulation factor VII, von Willebrand
factor, and tissue plasminogen activator; improving
platelet adhesiveness; and reducing bleeding time [5].
Several studies have been performed on patients under-
going various types of surgeries. A study in patientshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Shao et al. BMC Anesthesiology  (2015) 15:53 Page 2 of 5undergoing lumbar fusion showed that desmopressin
was effective in reducing intraoperative blood loss when
the anticipated bleeding exceeded 1 liter [6]. Another
study in patients undergoing orthognathic surgery showed
a significant reduction in intraoperative blood loss [7].
However, the effect of desmopressin administration on in-
traoperative blood loss in endoscopic sinus surgery is
unknown.
In addition to the effects desmopressin exerts on
hemostasis, it can also induce hypotension [8]. There is
general consensus that when FESS is performed under
general anesthesia, maintaining moderate, controlled
hypotension (mean arterial blood pressure [MAP], 60–
70 mm Hg) is important for improving surgical visibility.
This improvement results in faster surgery and a reduced
risk of complications, such as massive hemorrhage, skull
base defects, and blindness [9,10]. Permissive hypotension
and desmopressin have additive effects in reducing blood
loss for uncontrolled hemorrhage [11]. Although the mech-
anism of hypotension is unclear, desmopressin may have
combined beneficial effects on hemostasis and control of
hypotension, and thus on blood loss in endoscopic sinus
surgery patients. This study aimed to determine the effect
of administration of desmopressin on intraoperative blood
loss and the surgical field in patients undergoing endo-
scopic sinus surgery.Table 1 Quality of the intraoperative surgical field during
functional endoscopic sinus surgery
0–1 No bleeding; excellent to outstanding surgical conditions
2–3 Slight bleeding; surgery fairly easy. No stops for hemostasis
and/or suctioning are required
4–5 Slight bleeding; surgery mildly difficult. One stop for
hemostasis and/or suctioning is required
6–7 Moderate bleeding; surgery moderately difficult.
Occasional stops for hemostasis
8–9 Moderate to severe bleeding; surgery very difficult.
Multiple stops for hemostasis
10 Surgery terminated due to severe bleeding in the
surgical fieldMethods
We prospectively studied 90 American Society of
Anesthesiologists physical status I and II patients
with chronic rhinosinusitis presenting for bilateral
FESS. The trial was registered after the beginning of
the study (NCT 02125188). The study was approved
by the Medical Ethics Committee of the First Affiliated
Hospital of Sun Yat-sen University, Guangzhou, China.
Written informed consent was obtained from the patients.
All patients were 18–65 years old, and were first-time
candidates for two-side FESS. Specific exclusion criteria
were as follows: patients with a history of bleeding disor-
ders or taking medications that may affect surgical
hemostasis; secondary surgery; poorly controlled hyper-
tension or cerebrovascular disease; a history of significant
coronary artery disease or arrhythmias; a compromised
renal or hepatic function; and pregnancy. Patients were
randomly assigned to one of two study groups: patients in
the desmopressin group received 0.3 μg/kg of desmopres-
sin preoperatively and those in the control group received
normal saline instead. Assignment to the groups was per-
formed by computer-generated random numbers.
All patients had a normal preoperative platelet count
and coagulation test results. Anesthetic management of
all patients was standardized and conducted by a single
attending anesthesiologist. All of the surgeries wereperformed by a single, experienced surgeon. All of the
surgeons were blinded to the patient study groups.
Patients’ potential surgical predictors of intraoperative
blood loss were recorded before surgery. These predic-
tors included the presence of sinonasal polypoid disease
and endoscopically documented active infection, com-
puted tomography-graded severity of sinus disease based
on the Lund–MacKay scoring system [12], a history of
previous endoscopic sinus surgery, and a history of tak-
ing oral steroids within 2 weeks before surgery.
General anesthesia was induced with intravenous (IV)
fentanyl 3 μg/kg and propofol 2 mg/kg. Tracheal intub-
ation was facilitated with IV cisatracurium 0.2 mg/kg.
Intermittent positive pressure ventilation was followed to
maintain a normal end-tidal carbon dioxide partial pres-
sure. Shortly after induction, patients in the desmopressin
group received 0.3 μg/kg of desmopressin that was diluted
in 100 ml of normal saline. Patients in the control group
received 100 ml of normal saline IV over 20 min.
Anesthesia was maintained with bispectral index-
adjusted continuous IV infusions of propofol (50–140 μg
/kg/min) and remifentanil (0.15–0.3 μg/kg/ min), to
maintain MAP within 60–70 mmHg, as measured on
the patient’s arm every 5 min. Acute increases in MAP
were treated with additional boluses of IV remifentanil
(0.5–1 μg/kg) and escalating doses of IV esmolol (10–
20 mg), followed by incremental doses of IV nicardipine
(0.2–0.4 mg). Heart rate (HR) was recorded every 5 min.
Propofol and remifentanil infusions were discontinued
10–15 min before the end of the surgery. The duration
of surgery was recorded in all of the patients.
Local control of bleeding in the surgical field was facil-
itated by submucosal single time injection of epineph-
rine (1:100,000, 3 ml) by the surgeon. Crystalloid
solution was administered to replace overnight fluid def-
icits, provide maintenance fluid requirements, and re-
place blood loss on a 3:1 basis.
Final intraoperative blood loss was confirmed at the
end of each procedure by accounting for loss of blood
and irrigation fluid into the suction canister, the patient’s
Table 2 Patient’s demographic characteristics and






Age (yr) 45 (14.9) 40.7 (17.4) 0.2
Weight (kg) 62.7 (16.7) 59.0 (16.1) 0.3
Gender (M/F) 26/19 24/21 0.7
Surgical blood loss (mL) 42 (8.7) 70 (9.2) <0.001
Quality of surgical field (0–10) 4 (3–5) 7 (6-9) <0.001
Duration of surgery (min) 76 (20.7) 82 (19.6) 0.2
Polypoid disease (Y/N) 34/11 32/13 0.6
CT score (0–24) 15 (11–18) 13 (10–18) 0.6
Active infection (Y/N) 9/36 8/37 0.8
Preoperative steroids (Y/N) 16/29 11/34 0.3
Revision surgery (Y/N) 12/33 9/36 0.5
Data expressed as mean (SD) or median (interquartile range) where appropriate.
Figure 1 Flow chart. The chart shows that 116 patients were initially screened for the study and finally 90 patients were included in the
data analysis.
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nasopharyngeal packing (measured weight of packing on
the electronic scale). The overall quality of the surgical
field was assessed at the end of each procedure by the sur-
geon according to a scoring scale adapted from Boezaart
et al. [9] (Table 1). Possible side effects of desmopressin,
such as myocardial infarction, cerebral infarction, and
other thromboembolic complications, were investigated
by the surgeon.
We considered a 30% reduction in blood loss to be
clinically significant. To demonstrate this with a power
of 80% at the 0.05 level of significance, we calculated
that 45 patients would be required in each group. Re-
sults are expressed as mean, standard deviation, median,
and range. Parametric data were compared using the
Student’s t-test and non-parametric data were analyzed
with the chi-squared test and Mann–Whitney U test.
All statistical calculations were performed with SPSS
16.0. P < 0.05 was considered significant.
Results
A total of 90 patients were recruited, and all of the pa-
tients completed the study (Figure 1). All of the groups
were comparable with respect to demographic character-
istics and all surgical covariates (Table 2). There was asignificant effect of desmopressin on blood loss and
quality of the surgical field (Table 2). Although there
was a significant effect of treatment on MAP (Figure 2)
and HR (Figure 3) at several time points, mean MAP
and HR differences were small and transient.
Figure 2 Mean arterial blood pressure values in each of the groups over the course of surgery. The symbols show mean values. Data are presented at
10-min intervals, up to 80 min. The “0” and “End” values refer to the start and end of surgery, respectively. *P < 0.05 compared with the control group.
Shao et al. BMC Anesthesiology  (2015) 15:53 Page 4 of 5While the total dose of IV propofol and nicardipine
was not different between the study groups, patients in
the desmopressin group showed lower requirements for
IV remifentanil and esmolol than those in the control
group (Table 3). There were no postoperative thrombo-
embolic complications in any group.
The duration of surgery was shorter in the desmopres-
sin group than in the control group, but this difference
was not significant.
Discussion
Our study showed that preoperative desmopressin ad-
ministration reduced blood loss and improved the qual-
ity of the surgical field during FESS. These findings
indicated the potential clinical benefit of desmopressin
under our study conditions.
Several techniques have been suggested to reduce
bleeding in endoscopic sinus surgery. Wormald et al.
showed that injection of the pterygopalatine fossa re-
sulted in an improved surgical field during FESS [4].
Boezaart et al. compared sodium nitroprusside- and
esmolol-induced, controlled hypotension for FESS, and
found that the esmolol group showed superior surgical
conditions compared with the nitroprusside group [9].
Another study showed that preoperative administration
of oral clonidine reduced intraoperative blood loss andFigure 3 Heart rate in each of the groups over the course of surgery.
The symbols show mean values. Data are presented at 10-min intervals,
up to 100 min. The “0” and “End” values refer to the start and end of
surgery, respectively. *P < 0.05 compared with the control group.improved quality of the surgical field [13]. The present
study showed the efficacy of premedication with desmo-
pressin in reducing blood loss in FESS. This finding may
be attributed to the hemostatic effects of desmopressin,
which include an increase in plasma coagulation factor
VII, von Willebrand factor, and tissue plasminogen acti-
vator, and improvement of adhesiveness of platelets [5].
Proper anesthetic management can indirectly decrease
blood loss during FESS by improving the operating con-
ditions, which could result in a more rapid surgery [10].
Maintaining moderate, controlled hypotension is import-
ant for improving surgical visibility during FESS. Under
the conditions of moderate, controlled hypotension, the
quality of the surgical field is affected by achieving a re-
duction in HR, to promote superior hemodynamic sta-
bility and minimize direct peripheral vasodilation
[14,15]. These strategies were successfully used in our
study. There were no cases of considerable hypotension
(decrease >30% from baseline MAP) induced by desmo-
pressin in either of the study groups.
In our study, significantly smaller doses of IV remifen-
tanil and esmolol were required in the desmopressin
group than in the control group to maintain intraopera-
tive MAP within the desired range (Table 3). This find-
ing likely reflects the hypotensive effect of desmopressin
[8] and negative inotropic and direct vasodilating effects
of esmolol and remifentanil [9,16].
One limitation of this study was that we could not ad-
dress the severity of sinus disease in our patients.Table 3 Perioperative anesthetic and antihypertensive
drug requirements during functional endoscopic sinus
surgery
Desmopressin (n = 45) Control (n = 45) P
Propofol (mg) 830 (195) 780 (177) 0.2
Remifentanil (μg) 1350 (235) 1785 (260) <0.001
Esmolol (mg) 15 (4.5) 40 (7.5) <0.001
Nicardipine (mg) 0.25 (0.06) 0.26 (0.07) 0.5
Data expressed as mean (SD).
Shao et al. BMC Anesthesiology  (2015) 15:53 Page 5 of 5However, all of the patients in this study were first-time
candidates for two-sided FESS because of chronic sinus-
itis. In this study, we used a subjective scale to evaluate
the quality of the surgical field, as well as satisfaction of
the surgical team. The efficacy and reliability of this
measurement have been verified [17].
Because all pre-coagulative drugs (including desmo-
pressin) might have pro-thrombitic effects, the use of
desmopressin should be under a risk-benefit calculation
in patients with risk of hypercoagulability. Therefore, we
excluded patients with poorly controlled hypertension or
cerebrovascular disease, those with a history of signifi-
cant coronary artery disease or arrhythmias, and those
who were pregnant. And we didn’t find any postopera-
tive thromboembolic complications among the patients.
Conclusion
This study shows an independent effect of desmopressin
administration on blood loss and quality of the surgical
field during endoscopic sinus surgery that is performed
under propofol and remifentanil anesthesia, and under
moderate, controlled hypotension.
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